Nine biotech companies are set to make significant advances in 2024. Aiolos Bio, focusing on treatments for respiratory and inflammatory diseases, plans its phase 2 clinical trial. Capstan Therapeutics is developing treatments with precise cell engineering. Carisma Therapeutics is developing cancer treatments. Cellarity uses AI for drug discovery. Kriya Therapeutics is backed by $600 million for gene therapy development. Maze Therapeutics uses genetics to develop precision medicines. Quotient Therapeutics uses advanced sequencing technology. ReNAgade Therapeutics, with $300 million in funding, develops RNA medicines. OrsoBio focuses on therapies for severe metabolic disorders.
Group-IB’s Threat Intelligence and Defence Centre Equip Undergraduates with Sophisticated Cybersecurity Technologies to Boost Threat Analysis and Enhance Cyber Resilience for Campus Start-ups
Hey there from the heart of the San Francisco Bay Area! It’s an absolute pleasure to have you back again for our chat on some
